Statement of Changes in Beneficial Ownership (4)
December 14 2021 - 4:33PM
Edgar (US Regulatory)
FORM 4
[ ]
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
|
OMB APPROVAL
OMB Number:
3235-0287
Estimated average burden hours per response...
0.5
|
|
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
|
|
1. Name and Address of Reporting Person
*
Jindal Vineet R. |
2. Issuer Name and Ticker or Trading Symbol
Reneo Pharmaceuticals, Inc.
[
RPHM
]
|
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner __X__ Officer (give title below) _____ Other (specify below) Chief Financial Officer |
(Last)
(First)
(Middle)
C/O RENEO PHARMACEUTICALS, INC., 18575 JAMBOREE ROAD, SUITE 275-S |
3. Date of Earliest Transaction
(MM/DD/YYYY)
12/10/2021 |
(Street)
IRVINE, CA 92612
(City)
(State)
(Zip)
|
4. If Amendment, Date Original Filed
(MM/DD/YYYY)
|
6. Individual or Joint/Group Filing
(Check Applicable Line)
_X
_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
|
1.Title of Security (Instr. 3)
|
2. Trans. Date
|
2A. Deemed Execution Date, if any
|
3. Trans. Code (Instr. 8)
|
4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)
|
5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)
|
6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)
|
7. Nature of Indirect Beneficial Ownership (Instr. 4)
|
Code
|
V
|
Amount
|
(A) or (D)
|
Price
|
Common Stock | 12/10/2021 | | A | | 30000 (1) | A | $0.00 | 36600 (2) | D | |
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
|
1. Title of Derivate Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Trans. Date | 3A. Deemed Execution Date, if any | 4. Trans. Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
Stock option (right to buy) | $6.69 | 12/10/2021 | | A | | 100000 | | (3) | 12/9/2031 | Common Stock | 100000 | $0.00 | 100000 | D | |
Explanation of Responses: |
(1) | Represents a restricted stock unit award. |
(2) | Includes 1,600 shares acquired under the Issuer's 2021 Employee Stock Purchase Plan on December 8, 2021. |
(3) | The shares vest in a series of 48 successive equal monthly installments measured from December 10, 2021, subject to Reporting Person's Continuous Service (as defined in the Issuer's 2021 Equity Incentive Plan) as of each such vesting date. |
Reporting Owners
|
Reporting Owner Name / Address | Relationships |
Director | 10% Owner | Officer | Other |
Jindal Vineet R. C/O RENEO PHARMACEUTICALS, INC. 18575 JAMBOREE ROAD, SUITE 275-S IRVINE, CA 92612 |
|
| Chief Financial Officer |
|
Signatures
|
/s/ Vineet R. Jindal | | 12/13/2021 |
**Signature of Reporting Person | Date |
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Reneo Pharmaceuticals (NASDAQ:RPHM)
Historical Stock Chart
From Jul 2023 to Jul 2024